Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy.

@article{Morse2006ClinicalPO,
  title={Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy.},
  author={G. Daniel Morse and Linda M. Catanzaro and E. Pi{\~n}eiro Acosta},
  journal={The Lancet. Infectious diseases},
  year={2006},
  volume={6 4},
  pages={
          215-25
        }
}
The introduction of HIV-1 protease inhibitors and non-nucleoside reverse transcriptase inhibitors in 1996 began an era described as that of highly active antiretroviral therapy. In addition, the more recent development and availability of HIV-1 genotypic and phenotypic resistance tests and advances in pharmacological assays that support therapeutic drug monitoring (TDM) have created tools that may help clinicians to provide more individualised treatment with HIV-1 protease inhibitors. All… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 21 CITATIONS

Similar Papers

Loading similar papers…